# Eli Lilly's obesity drug data impresses analysts — jump back into the weight-loss leader

_AI-generated trading idea · LONG · LLY_

> Canonical page: https://commonquant.ai/research/for-you/eli-lilly-s-obesity-drug-data-impresses-analysts-jump-back-i--467a6112-ebcf-4801-9ec7-7a087b0b33cd

Eli Lilly's stock is climbing after presenting highly anticipated new data on its obesity and diabetes drugs at a major medical conference. Analysts confirm the company's lineup remains incredibly strong.

## Idea

The obesity drug market is shaping up to be one of the biggest opportunities in healthcare history. Eli Lilly just confirmed to Wall Street that its drug portfolio is robust and not reliant on just one product. With presentations at a major conference easing any competitive fears, the stock looks ready to continue its long-term climb higher.

## Advanced Analysis

### Verdict: strong thesis, wrong side of the entry rules — wait

The verdict: wait, don't enter. The strongest point for the idea is fundamental momentum — Q2 2026 revenue of $23.0B rose 16.0% sequentially with gross margin expanding to 85.8%, and operating cash flow jumped 200% quarter over quarter to $16.0B. The strongest point against is the rule set itself: the exit condition (a daily close below the 50-day EMA at $1,172.31) is already met, RSI(14) at 32.36 needs a recovery of about 7.6 points, and the walk-forward testing produced fewer than two profitable folds — fold 3 lost 4.0% with a 9% win rate — so no robust parameter setup was established. Ownership filings for the period ended June 30, 2026 show net open-market insider selling of roughly $2.9 million across 20 holders (coverage state: deadline passed, not current), a sentiment flag rather than a trigger. The dividend record — a payout growing 15.3% annually to $6.00 per share in 2025, and $6.69 over the trailing twelve months — gives the thesis a floor while the stock regains its footing. What would flip the call: a daily close back above the 50-day EMA with RSI(14) above 40 and a tag of the 21-day EMA at $1,192.52.

#### Conviction score breakdown

Composite score computed by the server from the applicable evidence-tier dimensions.

| Measure | Value |
| --- | ---: |
| Thesis support | 75/100 |
| Trade readiness | 25/100 |
| Risk quality | 50/100 |
| Backtest evidence | 45/100 |
| Fundamentals trend | 70/100 |
| Score | 53/100 |
| Composite Score | 53/100 |
| Evidence Tier | backtested |

#### Decision scenarios

Bull, base, and bear cases synthesized from the cited evidence tier. Likelihoods are rounded evidence-weighted judgments, not statistically calibrated forecasts.

| Measure | Value |
| --- | ---: |
| Evidence Tier | backtested |

### Trade now

This is a wait, not an entry. The strategy wants LLY held long when price is above the 50-day EMA, the 21-day EMA is tagged, and RSI(14) is above 40. Right now only one piece is in place: the last close of $1,149.62 sits below the 21-day EMA at $1,192.52, so the pullback condition is effectively met. But price is about $22.69 below the 50-day EMA at $1,172.31, and RSI(14) reads 32.36 — roughly 7.6 points under the required level of 40. The exit rule is also currently in its trigger state (price below the 50-day EMA), so no position should be carried today.

The historical evidence for this exact rule set over five years of daily bars is modest but real: an 8.4% total return across 39 trades, a 38.5% win rate, and a maximum drawdown of about 4.0%. The 12-month window alone returned roughly 3.0% with a 3.0% drawdown. Note that a bounded parameter search was run and no robust alternative setup was established — the configured rules stand as written.

Concretely, waiting means: watch for a daily close back above $1,172.31 (the 50-day EMA), RSI(14) recovering above 40, and a session in which the low touches or pierces $1,192.52 while the close holds at or above it. Until all of those line up, there is no trade. If an entry does trigger, the built-in risk controls are a hard stop at -6% from entry and a 10% take-profit; sizing is capped at 2% account risk per trade and a 20% maximum position. Skip any discretionary entry that arrives while price is below the 50-day EMA — that is precisely the condition the strategy treats as an exit.

#### LLY price and trigger map

Uses the idea timeframe and keeps price levels on the price axis.

| Measure | Value |
| --- | ---: |
| Ticker | LLY |
| Timeframe | 1d |

### The fundamentals are doing the heavy lifting behind the obesity narrative

The thesis here is straightforward: Eli Lilly's obesity franchise is durable, and the data presentation at the major medical conference (per the Bloomberg piece on June 8, 2026) reinforced that the pipeline isn't a single-product story. The fundamentals back that read. Full-year 2025 revenue came in at $65.2B, up 44.7% year over year, with a gross margin of 83.0% — and the momentum carried into 2026: Q2 revenue of $23.0B rose 16% sequentially from Q1's $19.8B, and gross margin expanded further…

#### LLY Return on equity

Return on equity trend from CommonQuant fundamentals/XBRL data; +124.6% from first to latest point.

| Measure | Value |
| --- | ---: |
| 2008-12-31 | \-0.3075084969648396% |
| 2009-06-30 | \0.13533878504672897% |
| 2009-09-30 | \0.3446138313982837% |
| 2009-09-30 | \0.09508329126703684% |
| 2009-12-31 | \0.45445287812457347% |
| 2010-03-31 | \0.1192949924968697% |
| 2010-06-30 | \0.13178900471896282% |
| 2010-09-30 | \0.10502599653379548% |
| 2010-12-31 | \0.4081624437412945% |
| 2011-03-31 | \0.07577758321252745% |
| Latest Value | \0.07577758321252745% |
| Change Pct | \124.642435562095% |
| Ticker | LLY |
| Timeframe | reported periods |

#### LLY Debt to equity

Debt to equity trend from CommonQuant fundamentals/XBRL data; -46.2% from first to latest point.

| Measure | Value |
| --- | ---: |
| 2008-12-31 | \0.685055731184232 ratio |
| 2009-06-30 | \0.7813084112149533 ratio |
| 2009-09-30 | \0.6834628975265018 ratio |
| 2009-12-31 | \0.6965344923519469 ratio |
| 2010-03-31 | \0.6366955640729094 ratio |
| 2010-06-30 | \0.670444442273309 ratio |
| 2010-09-30 | \0.562814880496554 ratio |
| 2010-12-31 | \0.545115657431785 ratio |
| 2011-03-31 | \0.36833115643524567 ratio |
| Latest Value | \0.36833115643524567 ratio |
| Change Pct | \-46.233402675352494 ratio |
| Ticker | LLY |
| Timeframe | reported periods |

#### LLY sector percentile check

Ranks LLY against 986 companies in its sector using CommonQuant fundamentals.

| Measure | Value |
| --- | ---: |
| Return on equity | \90.46653144016229th percentile |
| Gross margin | \79.30283224400871th percentile |
| Revenue growth (YoY) | \58.67269984917044th percentile |
| Ticker | LLY |
| Sector | Health Care |
| Peer Count | 986 |

### Scores

- **Conviction score breakdown:** 53
- **Thesis support:** 75
- **Trade readiness:** 25
- **Risk quality:** 50
- **Backtest evidence:** 45
- **Fundamentals trend:** 70

### Watch items

- **LLY — RSI (14)**
- **LLY — Daily close vs 50-day EMA**
- **LLY — Low vs 21-day EMA**
- **LLY — Price vs nearest support**
- **LLY — Dividend ex-date**
- **LLY — Price above EMA (50)**
- **LLY — Price**
- **LLY — RSI (14) above 40**
- **LLY — Price below EMA (50)**

## Key details

- Symbols: LLY
- Timeframes: 1D
- Tags: \#pharma, \#obesity, \#healthcare

## Community

- Upvotes: 10
- Views: 0
- Copies: 0
- Cosigns: 0

## News sources

- [Campbell's Earnings Beat; Eli Lilly Obesity Drug Results \| Stock Movers](https://www.bloomberg.com/news/videos/2026-06-08/campbell-s-earnings-beat-eli-lilly-obesity-drug-results-video) — Bloomberg

## Related

- [LLY trade ideas](https://commonquant.ai/markets/lly)
- [Latest market news](https://commonquant.ai/news)

## About CommonQuant Research

Ideas and Advanced Analysis are generated with fresh, LLM-selected news headlines and grounded in SEC XBRL fundamentals and peer percentiles. Strategies built from these ideas are automatically backtested (over a timeframe-dependent historical window with walk-forward tuning) and stress-tested before they can go live, then monitored against the news hourly while they run.